SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Stock Rally May Drive Strong Consumer Spending: Economist

MORE HEADLINES

» Markets | Economy | Companies

- Fed's Kohn Sees No Asset Bubbles Building in US

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 11 hrs ago
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

12 hrs ago

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

13 hrs ago

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

14 hrs ago

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 15 hrs ago
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Nov.18

11:00 AM ET

Tuesday, 18 Nov 2008

Novo Nordisk "Raises" Price On Treating Diabetes

Posted By:Mike Huckman

Topics:Medicine | Pharmaceuticals

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Alkermes Inc | Eli Lilly and Company | Amylin Pharmaceuticals | S | Merck & Co Inc

AP
Novo Nordisk, a company that has a vested interest in the diabetes market, is out with a new report today pegging the cost of treating the disease at nearly a quarter-trillion dollars.

According to the "National Changing Diabetes Program" which is sponsored by NVO, the "widely accepted" figure has been $174 billion. But Novo [NVO Loading... () ] commissioned The Lewin Group, a pharma consulting group, to broaden things out for what it's calling "The National Diabetes Economic Barometer." And all in, the study says a more accurate number for U.S. diabetes care and lost productivity in 2007 is $217.5 billion.

The report factors in an estimated additional $18 billion spent on treating more than six million Americans who don't know they have diabetes, $25 billion to take care of 57 million people with what's known as pre-diabetes, and $623 million on 180,000 pregnant women who got gestational diabetes.

Novo Nordisk has filed for Food and Drug Administration approval of a new type of once-a-day injectable diabetes drug. It's expected to get reviewed by an advisory committee next March. That's an outside panel of experts that recommends to the agency whether it should approve a drug. The FDA usually, but not always, follows the advice of such committees. Word is if it's approved NVO would call the drug "Victoza" for commercial purposes.

Study Finds Cost of Diabetes in the United States Exceeds $217 Billion

Is it too close to "victory" as in winning the battle against diabetes? I'm almost certain that if that's the brand name Novo wants that the FDA will scrutinize it. For now it's known by the mouthful liraglutide (lur-rag-loo-tide). If the drug comes to market it would compete against the twice-a-day injectable Byetta from Amylin Pharmaceuticals [AMLN Loading... () ] and the Januvia pill from Merck [MRK Loading... () ] . AMLN and its partners Eli Lilly [LLY Loading... () ] and Alkermes [ALKS Loading... () ] are also hoping to one-up NVO with a once-a-week version of Byetta, but the fate and timeline of that product is uncertain.

Some public health experts and advocates argue that new drugs aren't the solution to the fast-growing diabetes epidemic. They believe we need to move "upstream" with better education, eating and exercise habits and earlier diagnosis. Easier said than done.

Update: Novo Nordisk just issued this press release that the FDA advisory committee meeting on liraglutide has been postponed from March 2nd to April 2nd or 3rd. So, that means the potential FDA approval of the drug likely gets pushed into next year even further.